Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Status:
Not yet recruiting
Trial end date:
2023-03-20
Target enrollment:
Participant gender:
Summary
The study will be conducted in two periods, Period 1 (mass balance) and Period 2 (extension).
The purpose of Period 1 of this study is to provide a quantitative characterization of the
mass balance, rates and routes of elimination, and metabolic pathways after a single
intravenous administration of [14C]berzosertib. The purpose of Period 2 is to assess safety
and efficacy of berzosertib in combination with topotecan.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany